Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial

被引：8
|
作者：
Khoo, Chee W. [1 ]
Lip, Gregory Y. H. [1 ]
机构：
[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 04期
关键词：
atrial fibrillation; dabigatran; direct thrombin inhibitor; stroke; DESIGN;
D O I：
10.1517/14656560903530691
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Oral anticoagulants such as warfarin have been used widely for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has significant limitations and also requires frequent monitoring. Thus, there is an unmet need, with the quest for alternative oral anticoagulants with stable pharmacokinetics and pharmacodynamics that do not need monitoring. The paper under evaluation provides us with up-to-date information on the safety and efficacy of a new oral anticoagulant, dabigatran, compared with warfarin for stroke prevention in AF patients.</.
引用
收藏
页码：685 / 687
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    AMERICAN HEART JOURNAL, 2018, 198 : 169 - 177
  • [32] Clinical Experience with Dabigatran in Patients with Atrial Fibrillation: What Should the Hematologist Re-Ly on?
    Chapin, John
    Basciano, Paul
    DeSancho, Maria
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S181 - S181
  • [33] Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial
    Reinhardt, Samuel W.
    Desai, Nihar R.
    Tang, Yuanyuan
    Jones, Philip G.
    Ader, Jeremy
    Spertus, John A.
    PLOS ONE, 2021, 16 (08):
  • [34] Anemia is Associated with an Adverse Outcome in Patients with Atrial Fibrillation: Insights Form the Re-ly Trial
    Westenbrink, B. Daan
    Alings, Marco
    Connolly, Stuart
    Eikelboom, Iohn
    Ezekowitz, Michael D.
    Oldgren, Jonas
    Yang, Sean
    Pogue, Janice
    Yusuf, Salim
    Wallentin, Lars
    van Gilst, Wiek H.
    CIRCULATION, 2012, 126 (21)
  • [35] Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice
    Heidbuchel, Hein
    Verhamme, Peter
    ACTA CARDIOLOGICA, 2010, 65 (05) : 491 - 497
  • [36] Stroke prevention in atrial fibrillation: late-breaking insights from the RE-LY trial
    Wijnmaalen, A. P.
    NETHERLANDS HEART JOURNAL, 2009, 17 : 20 - 21
  • [37] RE-LY: dabigatran superior to warfarin irrespective of INR
    Fricker, Janet
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (10) : 550 - 550
  • [38] Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial
    Boehm, Michael
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Eikelboom, John W.
    Hohnloser, Stefan H.
    Reilly, Paul A.
    Schumacher, Helmut
    Brueckmann, Martina
    Schirmer, Stephan H.
    Kratz, Mario T.
    Yusuf, Salim
    Diener, Hans-Christoph
    Hijazi, Ziad
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (23) : 2481 - 2493
  • [39] Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)
    Ezekowitz, Michael D.
    Nagarakanti, Rangadham
    Noack, Herbert
    Brueckmann, Martina
    Litherland, Claire
    Jacobs, Mark
    Clemens, Andreas
    Reilly, Paul A.
    Connolly, Stuart J.
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION, 2016, 134 (08) : 589 - 598
  • [40] Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Yang, Sean
    Wallentin, Lars
    Ezekowitz, Michael
    Reilly, Paul
    Eikelboom, John
    Brueckmann, Martina
    Yusuf, Salim
    Connolly, Stuart J.
    CIRCULATION, 2012, 125 (05) : 669 - 676
12345